PEGS Summit Korea
PEGS Korea

트랙 1

단백질 엔지니어링과 항체 엔지니어링

9월 20일~21일

항체약물결합체(ADC) 및 이중특이성항체, 면역 조절 항체 등의 임상시험이 성공을 거두고 규제기관에 의한 승인이 잇따르면서 생물학적 치료 분야에 대한 관심은 그 어느 때보다 높아지고 있습니다. 임상시험 단계로 진행하는 신규 분자 표적약이 증가하는 가운데 신규 치료제의 엔지니어링과 설계 분야에서도 한계를 초월하는 새로운 표적 및 기술, 화학물질, 포맷이 다수 등장하고 있습니다.

단백질 엔지니어링과 항체 엔지니어링에 초점을 맞춘 이 트랙에서는 암치료 및 면역치료의 새로운 표적, 연구 및 진단용 항체의 표준화와 재현성에 관련된 문제가 논의되며, 중동 호흡기 증후군(MERS) 및 중증 열성 혈소판 감소 증후군(SFTS), 조류독감 바이러스, 에볼라 출혈열 등의 바이러스 감염증에 대응하는 항체에 대한 연구 발표, 이중특이성항체, ADC, 융합단백질, 외가닥 항체(scFv) 등의 새로운 분자 표적약을 위한 엔지니어링과 최적화를 위한 전략을 소개하는 세션 등이 예정되어 있습니다.

이 트랙에 이어 개최되는 암 면역치료에 관한 트랙에 참석하면 면역 체크포인트 저해제, T세포 양자면역치료, 병용 면역치료의 현재 개발 상황 및 전략, 임상시험의 최신 동향 등 다양한 정보를 파악할 수 있습니다.

아젠다 최종판

2016년 9월 20일(화)

7:30 등록, 커피

8:30 의장 개회사

Junho Chung, Ph.D., Professor, Biochemistry and Molecular Biology, Seoul National University


기조 강연

William Strohl8:40 항암제 및 메티실린 내성 황색 포도상 구균(MRSA) 감염증 치료제로서 이용 가능한 프로테아제 내성 항체

William R. Strohl, Ph.D., Vice President and Fellow, Janssen Biotherapeutics, Janssen Research & Development, LLC

Engineered antibodies with fit-for-purpose properties will differentiate next generation antibody therapeutics from traditional IgG1-based therapeutics. We have demonstrated that proteases secreted by invasive tumors and pathogens site-specifically cleave human IgG1, rendering it functionally inactive, as a potential mechanism for evading host immune response. We have engineered protease-resistant antibodies with potent cellkilling functions for use as anti-Staphylococcus aureus agents.

Dimiter Dimitrov9:20 새로운 바이러스 및 HIV-1에 대응하는 항체 기반 치료제 후보

Dimiter Dimitrov, Ph.D., Senior Investigator, Cancer Inflammation Program, National Cancer Institute, NIH

We identified and characterized a number of highly potent human antibodies and engineered antibody domains (eAds) against SARS- and MERS-CoVs (m336), Hendra and Nipah viruses (m102.4), and Dengue, as well as against HIV-1. m102.4 was administered to humans. m336 was successful in three animal models and showed great promise for further development. The eAd-based proteins against HIV-1 were successful in animal models and are being further developed for its eradication.


감염증에 대한 항체와 백신

10:00 휴식시간

10:30 중동호흡기증후군 코로나바이러스(MERS-CoV):한국에서 Drug Discovery의 기회

Ji-Young Min, Ph.D., Principal Investigator, Head, Respiratory Viruses Research Laboratory, Discovery Biology Department, Institut Pasteur Korea

Screening for and optimization of small molecule hits can provide a powerful compound by which the latent biology can be dissected to further our understanding of the biological processes. Presented in this talk are innovative phenomic approaches that are not only helping to shed a new light on the discovery of first-in-class compound with novel molecular mechanism of MERS-CoV infection, but also providing a great hope of fighting some of the more devastating outbreaks in new ways.

11:00 감염증 치료용 Celltrion의 항체 의약품 파이프라인

Kye Sook Yi, Ph.D., Senior Manager and Team Leader, New Antibody Development, R&D, Celltrion

Ebola virus disease and MERS are well-known infections where treatment has included convalescent plasma therapies for some patients. However, serum, and even purified polyclonal antibodies from serum, have several disadvantages. These include limitations in supply, safety concerns due to immunogenicity and viral contamination, and low specific titers. Here, we introduce our pipeline of new antibodies, developed using a platform technology, which target infectious diseases such as influenza A, Rabies and Hepatitis B virus.

11:30 Fc 엔지니어링과 감염증에 대응하는 항체 개발

Tianlei Ying, Ph.D., Professor, Antibody Engineering and Drug Discovery Group, Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, China

Therapeutic modalities based on monoclonal antibodies (mAbs) have shown clinical success in the treatment of many diseases. By using extraordinarily large human antibody libraries and in vitro display technologies, we have identified potent neutralizing mAbs against emerging infectious diseases and cancer. We are also applying antibody engineering techniques to rapidly develop cheaper, safer and more potent antibody-based therapeutics.

12:00 생물학적 치료제 개발 기간 단축:스케일러블 일렉트로포레이션법(Scalable Electroporation)을 이용한 멀티그램 스케일 수율에 의한 항체 생산

Peer Heine, Field Application Scientist, Research & Development, MaxCyte

Data developed with MaxCyte's flow electroporation will demonstrate the production of multiple grams of antibodies, bispecifics, and non-antibody like recombinant proteins following a single transient transfection. Its scalability with CHO, HEK293, insect cells, and other commonly used cells in bioproduction will be demonstrated as well as the rapid generation of high-yield stable cell lines(titer of 6 g/L) within 6-8 weeks of transfection. The glycosylation of stable vs. transiently produced protein will be examined

12:30 전시회장 오찬회, 포스터 발표 관람

13:55 의장 발언

Junho Chung, Ph.D., Professor, Biochemistry and Molecular Biology, Seoul National University

14:00 바이러스 감염증과 암에 대응하는 나노항체의 개발

Rui Gong, Ph.D., Professor & Head, Antibody Engineering Group, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences

Antibody constant CH2 domain is a promising scaffold for development of nanoantibodies that can not only bind to specific antigens but also offer certain Fc effector functions. Here, we report that new candidate clones against viral and tumor antigens were identified based on modified CH2 domain with increased stability and aggregation resistance. We show that the nanoantibody technology could be a useful platform for selection of nanoantibodies against various antigens with potential for further clinic use.

14:30 에피토프 기반 백신:입체구조 불연속 에피토프의 재구성

Jonathan M. Gershoni, Ph.D., Professor, Cell Research and Immunology, Tel Aviv University

Prophylactic vaccines elicit the production of antibodies intended to neutralize invading pathogens. The ability to focus this immune response towards neutralizing epitopes is a major challenge. We describe a method for the production of epitope-based immunogens where conformational discontinuous epitopes are functionally reconstituted. As a case in point we have reconstituted the receptor binding motif (RBM) of SARS Coronavirus and discuss this in the context of combating emerging Coronaviral diseases.

15:00 스폰서 제공 프레젠테이션

15:30 전시회장 휴식시간, 포스터 발표 관람


항체약물결합체(ADC)의 설계와 개발

16:15 탄수화물 표적화 항체를 이용한 세포독성약의 종양 특이적 전달

Felix Hart, Scientist, Preclinical Pharmacology & ADCs, Glycotope GmbH

Antibody-drug conjugates have great potential to specifically deliver cytotoxic agents to cancer cells. Carbohydrates on the surface of cancer cells represent promising targets for the specific delivery of cytotoxic drugs for cancer therapy. Tumor specificity and Fc-mediated effector functions were shown by immunohistochemistry and antibody-dependent cellular cytotoxicity, respectively. As prerequisites for intracellular drug delivery, target internalization upon antibody binding and lysosomal localization was confirmed. Moreover, surrogate ADCs using different cytotoxic agents inhibited proliferation of antigen-positive cancer cell lines.

16:45 부위 특이적 결합:항체약물결합체의 균일성 등 신약 개발로 연결되는 특성의 개선

Bruce Nianhe Han, Ph.D., CSO, NewBio Therapeutics

We have discovered new linkers, bis(maleimde)derivatives which can conjugate small molecule toxins to antibodies in site-specific manner. One of the advantages of this technology is that we don't need to do any antibody engineering and just use the interchain disulfide bonds of IgG to perform conjugation. The resulting final products have a high percentage of ADC with defined antibody-drug ratios. Also, these more homogeneous ADCs have shown improved in vitro and in vivo stability, and other related druggability properties.

17:15 안정적이며 유효한 부위 특이성 항체약물결합체의 전임상 개발 단축:비수식 항체에서 개변 트랜스글루타미나아제의 이용

Sean Hu, Ph.D., Founder, Dophen Biomed

Site-specific ADCs are made in a one-pot reaction directly from un-modified mAbs using engineered transglutaminase. Such ADCs are 4 to 8 times more efficacious in xenograft models than their counterparts of random conjugation via lysine residues and display wider therapeutic windows in GLP toxicology study. This platform uses your mAbs off the shelves and the reaction yields are as high as 98%, leaving no naked antibody to be removed. Thus, the manufacturing process is significantly simplified.

17:45 전시회장 리셉션, 포스터 발표 관람

18:45 첫째날 종료

2016년 9월 21일(수)

7:45 등록, 커피

8:30 의장 발언

Yong-Sung Kim, Ph.D., Professor, Molecular Science & Technology, Ajou University


항체 탐색과 항체 엔지니어링

8:40 차세대 다목적 바인더의 Discovery를 위한 혁신적인 하이스루풋(High-Throughput) 플랫폼

Jonas Schaefer, Ph.D., Head, High-Throughput Binder Selection Facility, Department of Biochemistry, University of Zurich

To optimize the efficiency and capacity of the laborious process of generating specific affinity reagents, we established a streamlined pipeline consisting of simultaneous selections against 94 targets and subsequent high-throughput screenings and validations. This fast and efficient platform allows the reliable discovery of recombinant binders to improve existing and to enable the development of novel innovative applications (from basic research to improved diagnostics) like elucidating intracellular pathways, amongst others.

9:10 자율적 인간 가변 영역(Autonomous Human Variable Domain) 기반 항체 라이브러리

Johan Nilvebrant, Ph.D., Researcher, Protein Technology, Royal Institute of Technology

We have constructed two synthetic libraries based on an engineered autonomous human variable heavy (VH) domain. We integrated a CDR design aimed to alleviate aggregation problems that are commonly associated with domain antibodies. Binders to all human Eph receptors, many of which are implicated in cancer, have been selected. The domain antibodies typically compete with ligand for binding and represent promising candidates to engineer novel receptor agonists and antagonists.

9:40 가변 영역 개변에 의한 안정적인 인간 항체 치료제 개발

Daniel Christ, Ph.D., Associate Professor and Director, Centre for Targeted Therapy, Immunology Program, Garvan Institute of Medical Research

Human antibody reagents often display poor biophysical properties and a propensity to aggregate. We have identified aggregation hotspots in the CDR regions of antibody variable domains, and have developed generally applicable strategies to overcome these limitations. Here we present recent advances in the application of the technology to antibody fragments, as well as to the stabilization of the FDA approved therapeutics and clinical candidates.

10:10 전시회장 휴식시간, 포스터 발표 관람


표적의 발견과 검증

10:50 펩티드/인간 백혈구 항원(HLA) 복합체를 표적으로 한 암치료용 항체

Julia Neugebauer, Ph.D., Assistant Director, Discovery, Alliances & Technologies, Morphosys AG

Tumor-specific peptide/HLA complexes make intracellular targets accessible to antibodies. However, the generation of therapeutic antibodies, which recognize a particular peptide/HLA complex specifically, is highly challenging. By identifying and applying appropriate counter-targets, we generated fully human, high affinity antibodies against a WT1 peptide/HLA complex. These antibodies bind to target-positive cancer cell lines and outperform similar state-of-the-art antibodies regarding target specificity and binding affinity.

11:20 시토졸 침투형 항체에 의한 세포내 발암 단백질의 표적화

Yong-Sung Kim, Ph.D., Professor, Molecular Science & Technology, Ajou University

The ability of an IgG-format antibody to reach the cytosol of target mammalian cells from outside of cells is highly desired for diverse purposes of research, diagnostic and therapeutic applications. In this talk, we will introduce a new antibody technology, in which human IgG-format antibody can access the cytosol of living cells after internalization and specifically bind to cytosolic oncogenic proteins, thereby showing anti-tumor efficacy.

11:50 혈관형성 억제 치료에서 새로운 표적으로서의 Clec14a:항체 기반 혈관내피세포성장인자(VEGF)의 표적화에 관련된 새로운 문제

Sukmook Lee, Ph.D., Principal Investigator, Research Center, Scripps Korea Antibody Institute

Clec14a is a type I transmembrane protein that is exclusively expressed on endothelial cells. In this talk, I will first highlight the relevance and role of clec14a in angiogenesis. With a human monoclonal antibody we have developed, I will also provide the proof-of-concept that antibody-based targeting of clec14a may be effective and the antibody has therapeutic potential for suppressing pathological angiogenesis for antibody therapy.

12:20 스폰서 제공 프레젠테이션

12:50 전시회장 오찬회, 포스터 발표 관람




* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.


Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English



기업 스폰서

 MaxCyte

기업 지원 스폰서


GeneScript

스폰서 조직


theAntibodySocietyLogo

Antibody Society Korea



Arrow Right Col미디어 파트너


 

트랙 1
Arrow Right Col 단백질 엔지니어링과 항체 엔지니어링


트랙 2
Arrow Right Col 암 면역치료




Catalog
국제컨퍼런스
Giievent
메일링 서비스